Embrace(TM) Hydrogel Embolic System
Instylla, Inc. · Decision date Oct 23, 2026
What did the FDA approve?
FDA records P250003/S008 as a supplement to PMA P250003, with the supplement type “Panel Track”. The recorded decision is approval, dated Oct 23, 2026.
FDA approval order statement
This device is indicated for embolization of hypervascular tumors in peripheral arteries = 5mm and peripheral arterial bleeds in vessels = 6mm.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 23, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P250003/S008
- Regulatory pathway
- PMA supplement
- Applicant
- Instylla, Inc.
- Product code
- QVG
- Decision code
- APPR
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Embolization Agent, Vascular.
- Applicant
- Instylla, Inc.
- Product code
- QVG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250003 · Original PMA
Embrace(TM) Hydrogel Embolic System
P250003/S008 received
Application receipt date recorded by FDA.
P250003/S009 · Related supplement
Embrace Hydrogel Embolic System
P250003/S010 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S011 · Related supplement
Embrace Hydrogel Embolic System
P250003/S008 · FDA decision
Panel Track
Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Instylla, Inc. | PMA approval | Aug 5, 2025 | FDA | |
Embrace Hydrogel Embolic SystemP250003/S009 | Instylla, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Embrace(TM) Hydrogel Embolic SystemP250003/S010 | Instylla, Inc. | PMA supplement | Oct 21, 2026 | FDA |
Embrace Hydrogel Embolic SystemP250003/S011 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Instylla, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., North Bldg., Bedford, MA, 01730
Sources and methodology
- Original FDA record: P250003/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

